Trial Profile
Real world use and outcomes of olaparib treatment in Swedish patients during the first three years following regulatory approval in different type of cancers
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Dec 2018
Price :
$35
*
At a glance
- Drugs Olaparib (Primary)
- Indications Breast cancer; Cancer; Ovarian cancer; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 03 Dec 2018 New trial record
- 14 Nov 2018 Results presented at the 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research